Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 257-264

  Etto, Leina ^a   Lacerda, Emílio ^a   Baiocchi, Otavio ^a   Silva, Vanderléia ^a   Dalboni, Maria ^a   Alves, Antonio ^a   Silva, Maria ^a   Vettore, André ^a   Colleoni, Gisele ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; FGF; HGF; Non Hodgkin lymphomas; Prognosis; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD34 ANTIGEN; CYTOKINE; PARAFFIN; SCATTER FACTOR; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38849126729     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701769640     Document Type: Article

References (41)

1. Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R. and Li, T. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, pp. 964-967.
2. Risau, W. (1997) Mechanisms of angiogenesis. Nature, 386, pp. 671-674.
3. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, pp. 27-31.
4. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, pp. 353-364.
5. Miyazawa, K., Shimomura, T., Naka, D. and Kitamura, N. (1994) Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem, 269, pp. 8966-8970.
6. van der Voort, R., Taher, T. E., Derksen, P. W., Spaargaren, M., van der Neut, R. and Pals, S. T. (2000) The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res, 79, pp. 39-90.
7. Birchmeier, C., Birchmeier, W., Gherardi, E. and Wounde, G F Vande (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol, 4, pp. 915-925.
8. Trusolino, L. and Comoglio, P. M. (2002) Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat Rev Cancer, 2, pp. 289-300.
9. Dvorak, H. F., Brown, L. F., Detmar, M. and Dvorak, A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146, pp. 1029-1039.
10. Friesel, R. E. and Maciag, T. (1995) Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J, 9, pp. 919-925.
11. Salven, P., Teerenhovi, L. and Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, pp. 3167-3172.
12. Salven, P., Teerenhovi, L. and Joensuu, H. (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood, 94, pp. 3334-3339.
13. Salven, P., Orpana, A., Teerenhovi, L. and Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood, 96, pp. 3712-3718.
14. Hsiao, L. T., Lin, J. T., Yu, I. T., Chiou, T. J., Liu, J. H. and Yen, C. C. (2003) High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Haematol, 70, pp. 282-289.
15. Jaffe, E., Harris, N. L., Stein, H. and Vardiman, J. W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon
16. NCCN. National Comprehensive Cancer Network The complete library of practice guidelines in oncology (online)
17. Weidner, N., Semple, J. P., Welch, W. R. and Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med, 324, pp. 1-8.
18. Hazar, B., Paydas, S., Zorludemir, S., Sahin, B. and Tuncer, I. (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma, 44, pp. 2089-2093.
19. Arias, V. and Soares, F. A. (2000) Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: A morphometric study. Leuk Lymphoma, 40, pp. 157-166.
20. Koster, A., van Krieken, J HM, MacKenzie, M. A., Schraders, M., Borm, G. F. and van der Laak, J AWM (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res, 11, pp. 154-161.
21. Ridell, B. and Norrby, K. (2001) Intratumoral microvascular density in malignant lymphomas of B-cell origin. APMIS, 109, pp. 66-72.
22. Dammacco, F., Iurlaro, M., Ria, R., Quondamatteo, F., Nico, B. and Giacchetta, F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer, 79, pp. 965-970.
23. Gratzinger, D., Zhao, S., Marinelli, R. J., Kapp, A. V., Tibshirani, R. J. and Hammer, A. S. (2007) Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphomas subtypes. Am J Pathol, 170, pp. 1362-1369.
24. Jorgensen, J. M., Sorensen, F. B., Bendix, K., Nielsen, J. L., Olsen, M. L. and Funder, A. M. (2007) Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma, 48, pp. 584-595.
25. Giles, F. J., Vose, J. M., Do, K., Johnson, M. M., Manshouri, T. and Bociek, G. (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res, 28, pp. 595-604.
26. Pedersen, L. M., Klausen, T. W., Davidsen, U. H. and Johnsen, H. E. (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin lymphoma. Ann Hematol, 84, pp. 510-516.
27. Arrieta, O., Garcia, E., Guevara, P., Garcia-Navarrete, R., Ondarza, R. and Rembao, D. (2002) Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer, 94, pp. 3210-3218.
28. Kim, C. H., Lee, J. S., Kang, S. O., Bae, J. H., Hong, S. P. and Kahng, H. (2007) Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol, 43, pp. 1021-1025.
29. Eichbaum, M. H., de Rossi, T. M., Kaul, S., Bruckner, T., Schneeweiss, A. and Sohn, C. (2007) Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol, 28, pp. 36-44.
30. Niitsu, N., Okamoto, M., Nakamine, H., Yoshino, T., Tamaru, J-I and Nakamura, S. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol, 68, pp. 91-100.
31. Aref, S., Mabed, M., Zalata, K., Sakrana, M. and Askalany, H El (2004) The interplay between c-myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble flt-1 in diffuse large B cell lymphoma (DLBCL): Relationship to patient outcome. Leuk Lymphoma, 45, pp. 499-506.
32. Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A. and Ferrucci, P. F. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol, 106, pp. 504-509.
33. Jacob, C., Sterz, J., Zavrski, I., Heider, U., Kleeberg, L. and Fleissner, C. (2006) Angiogenesis in multiple myeloma. Eur J Cancer, 42, pp. 1581-1590.
34. Shanafelt, T. D. and Kay, N. E. (2006) The clinical and biological importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol, 33, pp. 174-185.
35. Kuppers, R., Klein, U., Hansmann, M. L. and Rajewsky, K. (1999) Cellular origin of human B-cell lymphomas. N Engl J Med, 341, pp. 1520-1529.
36. Tjin, E PM, Groen, R WJ, Vogelzang, I., Derksen, P WB, Klok, M. D. and Meijer, H. P. (2006) Functional analysis of HGF/MET signaling and aberrant HGF-activation expression in diffuse large B-cell lymphoma. Blood, 107, pp. 760-768.
37. Cao, H., Björndahl, M. A., Gallego, M. I., Chen, S., Religa, P. and Hansen, A. J. (2006) Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood, 107, pp. 3531-3536.
38. Krause, D. S. and Van Etten, R. A. (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353, pp. 172-187.
39. Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R. and Yamazaki, S. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res, 67, pp. 4408-4417.
40. Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K. and Tsuruda, T. (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/ c-Met-dependent human tumors. Cancer Res, 66, pp. 1721-1729.
41. Kim, K. J., Wang, L., Su, Y. C., Gillespie, G. Y., Salhotra, A. and Lal, B. (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res, 12, pp. 1292-1298.